Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quest LaboratoriesNSE:QUESTLAB -0.61%46 Days Payable is 27.11 as of Mar. 2026, which is 75% below its 10-year median of 110.34. GuruFocus rates NSE:QUESTLAB with a GF Score™ of 46/100. The stock has 5 warning signs investors should review. Among 925 Drug Manufacturers companies, Quest Laboratories ranks worse than 91.46% on this metric.
The historical rank and industry rank for Quest Laboratories's Days Payable or its related term are showing as below:
NSE:QUESTLAB'
s Days Payable Range Over the Past 10 Years
Min: 23.65 Med: 110.34 Max: 177.77
Current: 27.94
During the past 6 years, Quest Laboratories's highest Days Payable was 177.77. The lowest was 23.65. And the median was 110.34.
NSE:QUESTLAB's Days Payable is ranked worse than 91.46% of 925
companies
in the Drug Manufacturers industry
Industry Median: 89.79
vs NSE:QUESTLAB: 27.94
Quest Laboratories's Days Payable
increased
from Mar. 2025 (18.45) to Mar. 2026 (27.11).
It may suggest that Quest Laboratoriesdelayed paying its suppliers.
The historical data trend for Quest Laboratories's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:QUESTLAB vs LLY, JNJ, ABBV: Days Payable Comparison
For the Drug Manufacturers - General subindustry, Quest Laboratories's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest Laboratories Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Quest Laboratories's Days Payable distribution charts can be found below:
* The bar in red indicates where Quest Laboratories's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Quest Laboratories's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest Laboratories (NSE:QUESTLAB) has a Days Payable of 27.11 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Quest Laboratories and its competitors. This is 75% below median its historical median of 110.34. Over the past decade, Quest Laboratories' Days Payable has ranged from 23.65 to 177.77. According to the industry distribution chart, Quest Laboratories ranks #846 out of 925 companies in the Drug Manufacturers industry, placing it in the top 91.5%.
Is Quest Laboratories' Days Payable too high?
Quest Laboratories' current Days Payable of 27.11 is 75% below median its 10-year median of 110.34. Over the past 10 years, this metric has ranged from a low of 23.65 to a high of 177.77. The Drug Manufacturers industry median Days Payable is 89.79. Quest Laboratories' value of 27.11 is 69.8% below this industry median. Based on the distribution chart, Quest Laboratories ranks #846 out of 925 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Quest Laboratories has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Quest Laboratories' Days Payable compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Quest Laboratories ranks #846 out of 925 companies for Days Payable. This places Quest Laboratories in the lower half of its industry. The industry median Days Payable is 89.79. Quest Laboratories' value of 27.11 is 69.8% below this benchmark. Historically, Quest Laboratories' own Days Payable has ranged from 23.65 to 177.77 over the past decade. While the company's 10-year median is 110.34 vs. the industry median of 89.79, Quest Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 89.79, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quest Laboratories's current Days Payable of 27.11 is 69.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Quest Laboratories and its competitors. For the Drug Manufacturers industry, the median Days Payable is 89.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quest Laboratories's current Days Payable is 27.11, which is 75% below median its own 10-year median of 110.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Laboratories stock overvalued right now?
Quest Laboratories (NSE:QUESTLAB) has a current Days Payable of 27.11. The current Days Payable is 27.11, which is 75% below median its 10-year median of 110.34 and 69.8% below the Drug Manufacturers industry median of 89.79. Quest Laboratories' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Quest Laboratories (NSE:QUESTLAB), the current Days Payable is 27.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quest Laboratories Ltd is engaged in the business of manufacturing pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. It produces various products, comprising ethical drugs, generic drugs, and over-the-counter drugs, and is also available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids, among others. The company operates in a single segment of Drugs and Chemicals.
46GF Score
Get the complete analysis for NSE:QUESTLAB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QUESTLAB has been successfully added to your 
